Therapeutic targeting of STAT3 by monobodies
An international consortium headed by the Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences ETH Lausanne collaborated with Veronika Sexl group members and developed the first monobodies targeted against STAT3. Monobodies are synthetic binding proteins engineered to selectively bind intracellular proteins – also those lacking an enzymatic domain. High affinity STAT3 monobodies were identified in a combinatorial phage and yeast display library sorting screen. The authors show selective interference of the monobodies with cellular STAT3 activity. This is an attractive therapeutic option due to STAT3’s homology with other STAT proteins that complicates the development of selective inhibitors.
Published in Nature Communications
Grégory La Sala, Camille Michiels, Tim Kükenshöner, Tania Brandstoetter, Barbara Maurer, Akiko Koide, Kelvin Lau, Florence Pojer, Shohei Koide, Veronika Sexl, Laure Dumoutier & Oliver Hantschel
Selective inhibition of STAT3 signaling using monobodies targeting the coiled-coil and N-terminal domains